This strategy has been applied in the context of hemophilia B, to insert a corrective F9 cDNA into the second exon of the F9 gene using ZFN or CRISPR/Cas9 (Li et al., 2011; Sharma et al., 2015; Wang L. et al., 2019) or the 3′end of the albumin safe harbor (Lisjak et al., 2022). Here, F9 is linked to hemophilia B.